港股异动 | 腾盛博药-B(02137)再涨超10%破顶近三日累涨近80% 总市值已突破300亿港元_老虎社区_美港股上老虎

港股异动 | 腾盛博药-B(02137)再涨超10%破顶近三日累涨近80% 总市值已突破300亿港元

智通财经2021-08-10

智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

ZN节节高
·2021-08-10
💰
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2158429616?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825","is_english":false,"pubTime":"2021-08-10 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2158429616","market":"hk","top_or_hot":-1,"title":"港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/530668.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 09:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/530668.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/530668.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/530668.html","article_id":"2158429616","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2158429616","pubTimestamp":1628559311,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02137":"腾盛博药-B"},"translate_title":"Hong Kong stocks changed Tengsheng Boyao-B (02137) rose by more than 10%, broke the peak, and rose by nearly 80% in the past three days. The total market value has exceeded HK $30 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":896832755,"gmtCreate":1628567285177,"gmtModify":1628567285177,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"htmlText":"💰","listText":"💰","text":"💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896832755","repostId":2158429616,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}